Martin Vos1, Elsemieke I Plasmeijer2, Barbara C van Bemmel3, Wim van der Bij4, Nina S Klaver1, Michiel E Erasmus5, Geertruida H de Bock6, Erik A M Verschuuren4, Emőke Rácz7. 1. Department of Dermatology and Venereology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 2. QIMR Berghofer Medical Research Institute, Cancer and Population Studies, Brisbane, Queensland, Australia. 3. Department of Pathology, Martini Hospital, Groningen, The Netherlands. 4. Departments of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 5. Cardiothoracic Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 6. Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 7. Department of Dermatology and Venereology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: e.racz@umcg.nl.
Abstract
BACKGROUND: Chronic immunosuppression after solid-organ transplantation is a risk factor for cutaneous squamous cell carcinoma (cSCC) development. Certain immunosuppressant drugs, namely azathioprine and calcineurin inhibitors, increase this risk more than others. We investigated incidence of cSCC in a Dutch lung transplant recipient (LTR) cohort and analyzed associated risk factors. METHODS: All LTRs with post-transplant survival of >30 days were included. Data included indication for lung transplantation and duration of medication use. Skin cancer data were extracted from the Dutch nationwide registry of histopathology (PALGA). Uni- and multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression analyses. RESULTS: Five hundred forty-four patients were included with a median survival of 11.05 years. Fifty-two (9.6%) LTRs developed at least one cSCC, with a cumulative incidence of 3.9% and 15.3% after 5 and 10 years, respectively. Multivariate analyses showed that the sequential use of azathioprine and mycophenolate mofetil (MMF), both at for least 1 year, was associated with a lower risk of developing cSCC (hazard ratio [HR] 0.24; 95% confidence interval [CI] 0.10 to 0.56) compared with azathioprine use only. Furthermore, age at transplantation (HR 3.42; 95% CI 1.33 to 8.79), male gender (HR 1.75; 95% CI 1.00 to 3.05), previous skin cancer (HR 4.75; 95% CI 1.14 to 19.76), and history of smoking (HR 3.30; 95% CI 1.69 to 6.44) were associated with increased risk of developing cSCC in univariate analyses. CONCLUSIONS: Apart from known risk factors, we found that switching from azathioprine to MMF is associated with reduced incidence of cSCC in LTR, prompting a discussion of whether switching azathioprine to MMF should be considered in high-risk patients.
BACKGROUND: Chronic immunosuppression after solid-organ transplantation is a risk factor for cutaneous squamous cell carcinoma (cSCC) development. Certain immunosuppressant drugs, namely azathioprine and calcineurin inhibitors, increase this risk more than others. We investigated incidence of cSCC in a Dutch lung transplant recipient (LTR) cohort and analyzed associated risk factors. METHODS: All LTRs with post-transplant survival of >30 days were included. Data included indication for lung transplantation and duration of medication use. Skin cancer data were extracted from the Dutch nationwide registry of histopathology (PALGA). Uni- and multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression analyses. RESULTS: Five hundred forty-four patients were included with a median survival of 11.05 years. Fifty-two (9.6%) LTRs developed at least one cSCC, with a cumulative incidence of 3.9% and 15.3% after 5 and 10 years, respectively. Multivariate analyses showed that the sequential use of azathioprine and mycophenolate mofetil (MMF), both at for least 1 year, was associated with a lower risk of developing cSCC (hazard ratio [HR] 0.24; 95% confidence interval [CI] 0.10 to 0.56) compared with azathioprine use only. Furthermore, age at transplantation (HR 3.42; 95% CI 1.33 to 8.79), male gender (HR 1.75; 95% CI 1.00 to 3.05), previous skin cancer (HR 4.75; 95% CI 1.14 to 19.76), and history of smoking (HR 3.30; 95% CI 1.69 to 6.44) were associated with increased risk of developing cSCC in univariate analyses. CONCLUSIONS: Apart from known risk factors, we found that switching from azathioprine to MMF is associated with reduced incidence of cSCC in LTR, prompting a discussion of whether switching azathioprine to MMF should be considered in high-risk patients.
Authors: Donal J Sexton; Patrick O'Kelly; Eamonn O'Leary; Susan Murray; Sandra Deady; Fergus Daly; Jim Egan; Diarmaid D Houlihan; P Aiden McCormick; Patrick G Morris; Siona Ni Raghallaigh; Fergal J Moloney; James Paul O'Neill; Peter J Conlon Journal: JAMA Dermatol Date: 2019-05-01 Impact factor: 10.282
Authors: Anne Zaremba; Eleftheria Chorti; Finja Jockenhöfer; Saskia Bolz; Selma Sirin; Martin Glas; Jürgen C Becker; Selma Ugurel; Alexander Roesch; Dirk Schadendorf; Elisabeth Livingstone; Tim Hagenacker; Lisa Zimmer Journal: J Immunother Cancer Date: 2019-05-29 Impact factor: 13.751
Authors: Jean Christopher Chamcheu; Tithi Roy; Mohammad Burhan Uddin; Sergette Banang-Mbeumi; Roxane-Cherille N Chamcheu; Anthony L Walker; Yong-Yu Liu; Shile Huang Journal: Cells Date: 2019-07-31 Impact factor: 6.600
Authors: Thibault Letellier; Florent Le Borgne; Clarisse Kerleau; Aurélie Gaultier; Jacques Dantal; Simon Ville Journal: Clin J Am Soc Nephrol Date: 2020-11-10 Impact factor: 8.237